Innovative Medicines Initiative (IMI-2) Call

The Innovative Medicines Initiative (IMI-2) Has Launched a Call for the Development of Therapeutics and Diagnostics Combatting Coronavirus Infections 

The purpose of the Innovative Medicines Initiative (IMI-2), of which Turkey is also a partner of under the Horizon 2020 Programme, is to improve health by accelerating the development and access of innovative medicines for patients, especially in areas where there are insufficient medical solutions or social needs.

On the 3rd of March 2020, the IMI-2 21st Call has been launched against the coronavirus pandemic. Applications for the call “Development of therapeutics and diagnostics combatting coronavirus infections” can be carried out through the European Commission portal until the 31st of March 2020.

Scope of the Call:

Proposals submitted under this topic are expected to advance the knowledge specifically on COVID-19 and more widely on the coronavirus family with the aim of contributing to an efficient patient management and/or public health preparedness and response to current and future outbreaks of coronavirus infection.

Considering that this is a newly identified virus, the scope of this topic remains broad and must address at least one of the following objectives:

  • Development of therapeutics to address a rapid response towards the current COVID-19 outbreak: relevant “clinical ready”-assets include approved therapies or compounds in development, which could be repurposed for use in treating patients with the coronavirus.
  • Development of therapeutics to address the current and/or future coronaviruses outbreaks: identification of new potential assets and approaches that could be utilised including preventive strategies and combination approaches and could also address potential resistance. This may also include optimisation of promising treatments used in rapid response (e.g. reformulation).
  • Development of diagnostics, ensuring rapid evaluation of candidates based on existing technologies, to allow for fast case detection and surveillance.
  • Development of fast and reliable detection of COVID-19 carriers and symptomatic individuals suspected of COVID-19 infection. This can be achieved through point of care (POC) testing or centralised testing.

Please note that preventive vaccines are specifically excluded from the scope of the call.

Expected Impact:

Proposals must be timely, with rapid activation, to enable early and valuable outcomes to be established and should contribute to one or more of the following impacts:

  • Fast track development and availability of therapeutics and/or diagnostics to be used in the clinical management of patients infected by COVID-19 and/or future outbreaks of coronaviruses, and to ensure that a variety of drugs are available for patients, including tackling resistance, and combination therapy.
  • Contribution to the public health preparedness and response in the context of the ongoing epidemic of COVID-19 and/or future outbreaks of pan-coronaviruses.
  • Significant impact on global health, both at the individual and the public health level by leading to results that have a direct impact for persons at risk of exposure to coronavirus or for patients suffering from coronavirus disease.

Call Budget: IMI-2 Joint Undertakin has allocated 45 Million Euros. Additionally, EFPIA companies and IMI2 Associated Partners will also contribute approximately 45 Million Euros.

Call publication date: 3 March 2020

Submission start date: 3 March 2020

Submission deadline: 31 March 2020 17:00 (Central European Time, CET)

For more information about the call, click here: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/imi2-2020-21-01